Riskpilot← Back to searchSign inGet full accessNordic Implantat AB
ABActiveOrg 5591528186Övre Eneborgsvägen 30Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20181 employees
Revenue 2025
SEK 1,7M
+15% vs 2024
EBITDA margin
4.5%
-77% vs 2024
Equity ratio
79.7%
Financial strength
Net profit 2025
SEK 56K
-80% vs 2024
| Revenue | SEK 1,7M | +15% |
| EBITDA | SEK 78K | -77% |
| Net profit | SEK 56K | -80% |
| Total assets | SEK 794K | -56% |
| Equity | SEK 633K | -41% |
| Employees | 1 | — |
Legal name
Nordic Implantat AB
Org number
5591528186
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
16 mars 2018
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-02-28
Financial year
January – December
Signatory rights
Firman tecknas i förening av ledamoten suppleanten
Company purpose
Bolaget fokuserar på att hitta nya produkter, varumärken till tandvård och därmed förenlig verksamhet. Äga, hyra ut och förvalta fastigheter samt därmed förenlig verksamhet.
Address
Övre Eneborgsvägen 30
Email
nordicimplantat@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 331 | 1 998 | 2 666 | 1 500 | 1 723 |
| Staff expenses | — | — | — | −347 | — |
| EBITDA | 95 | 242 | 876 | 337 | 78 |
| Depreciation & amort. | −82 | −84 | −0 | — | −0 |
| EBIT | 13 | 158 | 876 | 337 | 78 |
| Net financials | — | — | — | 6 | −6 |
| Profit before tax | 13 | 158 | 875 | 343 | 72 |
| Tax | −0 | −16 | −180 | −70 | −16 |
| Net profit | 13 | 142 | 695 | 274 | 56 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 663 | 803 | 2 002 | 1 811 | 794 |
| Equity | −34 | 108 | 803 | 1 077 | 633 |
| Long-term debt | 521 | 208 | 415 | 437 | 4 |
| Short-term debt | 176 | 487 | 784 | 297 | 157 |
| Total debt | 697 | 695 | 1 199 | 734 | 161 |
EBITDA margin
4.5%
This company
15.8%
Market median
-72% vs market
20212025
Equity ratio
79.7%
This company
38.2%
Market median
+109% vs market
20212025
Return on equity
8.8%
This company
18.4%
Market median
-52% vs market
20212025
Net profit margin
3.3%
This company
8.1%
Market median
-59% vs market
20212025
Asset turnover
2.17×
This company
1.12×
Market median
+94% vs market
20212025
Debt / equity
0.25×
This company
0.62×
Market median
+60% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-03-01 – 2025-02-28
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-03-01 – 2024-02-29
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-03-01 – 2023-02-28
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-03-01 – 2022-02-28
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-03-01 – 2021-02-28
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nordic Implantat AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Raed Al-Khafaji | Deputy Board Member | 0 companies |
| Sarah Chawich Barkaji | Deputy Board Member | 0 companies |
| Gamal Salim Abu Qatma | Board of Directors | 0 companies |